An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Xadago

Chemical Namesafinamide
Dosage FormTablet (oral; 50, 100 mg)
Drug ClassInhibitors
SystemMusculoskeletal, Nervous
CompanyUS Worldmeds
Approval Year2017

Indication

  • To treat Parkinson’s disease in conjunction with levodopa/carbidopa.
Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xadago (Safinamide) Prescribing Information 2017US WorldMeds, LLC, Louisville, KY
Document TitleYearSource
Clinical review report: safinamide (onstryv). 2020CADTH
Pharmacoeconomic review report: safinamide (onstryv).2020CADTH
Parkinson’s disease with motor fluctuations: safinamide. 2017NICE
Document TitleYearSource
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis.2020European Journal of Clinical Pharmacology
A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease. 2019F1000Research
Comprehensive examination of therapies for pain in Parkinson’s disease: A systematic review and meta-analysis. 2018Neuroepidemiology
A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. 2018British Journal of Clinical Pharmacology